ORGOVYX DIN 02542137
Health Canada record
| Active ingredient(s) | RELUGOLIX 120 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | L02BX04 RELUGOLIX |
| Original market date | 06-Dec-2023 |
| Current status date | 05-Nov-2025 |
| Source | Health Canada DPD |
Establishment licence of the holder
Knight Therapeutics Inc. — licence 3-002350, currently licensed, last inspection rating C (2025-11-05).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing RELUGOLIX
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02541742 | MYFEMBREE | KNIGHT THERAPEUTICS INC. | Tablet | RELUGOLIX 40 MG; ESTRADIOL 1 MG; NORETHINDRONE ACETATE 0.5 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 36327 | 2025-11-05 | New Drug Submission (NDS) | Administrative: Change in product ownership |
| 31810 | 2023-10-10 | New Drug Submission (NDS) |
International API supply for RELUGOLIX
17 active FDA Drug Master Files.
Request a quote for ORGOVYX